BackNewron Pharmaceuticals S.p.A. Overview
Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. Return on Equity

Newron Pharmaceuticals S.p.A. (NP5.DE) has a ROE of 35.45%, above the Healthcare sector average of -100.59%.

Get informed when a big investor buys or sells

+ Follow

ROE

35.45%

Return on Equity

35.45%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Newron Pharmaceuticals S.p.A. (NP5.DE) FAQ

The latest ROE for NP5.DE is 35.45%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Newron Pharmaceuticals S.p.A.'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, NP5.DE currently prints 35.45% for ROE, while the sector average sits near -100.59%. That is roughly 135.2% above the sector mean. Large gaps often invite a closer look at Newron Pharmaceuticals S.p.A.'s growth, margins, and balance sheet.

Return on Equity shows how effectively Newron Pharmaceuticals S.p.A. converts resources into returns. At 35.45%, NP5.DE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NP5.DE's ROE (35.45%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Newron Pharmaceuticals S.p.A.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.